Riskpilot← Back to searchSign inGet full accessREMOVAID AS
ASActiveOrg 998554403Ytrebygdsvegen 215, 5258 BlomsterdalenResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20125 employeeswww.removaid.com
Revenue 2024
NOK 100K
+442% vs 2023
EBITDA margin
-11091.6%
-1% vs 2023
Equity ratio
22.1%
Financial strength
Net profit 2024
NOK -11,6M
-4% vs 2023
| Revenue | NOK 100K | +442% |
| EBITDA | NOK -11,1M | -1% |
| Net profit | NOK -11,6M | -4% |
| Total assets | NOK 1,4M | -85% |
| Equity | NOK 319K | -96% |
| Employees | 5 | — |
Legal name
REMOVAID AS
Org number
998554403
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
28. juni 2012
Share capital
NOK 4 464 037
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene. Daglig leder og styrets leder i fellesskap.
Company purpose
Utvikling av medisinsk utstyr og alt som står i forbindelse hermed.
Address
Ytrebygdsvegen 215, 5258 Blomsterdalen
Phone
+4793289105
Email
admin@removaid.com
Website
www.removaid.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 8 | 18 | 100 |
| Staff expenses | −1 168 | −4 023 | −3 597 | −4 974 | −2 816 |
| EBITDA | −3 664 | −9 258 | −7 926 | −10 978 | −11 119 |
| Depreciation & amort. | −85 | −95 | −96 | −96 | −462 |
| EBIT | −3 748 | −9 353 | −8 022 | −11 074 | −11 582 |
| Net financials | −89 | −33 | 6 | −59 | −3 |
| Profit before tax | −3 837 | −9 386 | −8 016 | −11 133 | −11 585 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −3 837 | −9 386 | −8 016 | −11 133 | −11 585 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 23 735 | 15 481 | 17 371 | 9 422 | 1 444 |
| Equity | 22 463 | 13 077 | 16 086 | 7 904 | 319 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 272 | 2 404 | 1 285 | 1 518 | 1 125 |
| Total debt | 1 272 | 2 404 | 1 285 | 1 518 | 1 125 |
EBITDA margin
-11091.6%
This company
15.8%
Market median
-70300% vs market
20202024
Equity ratio
22.1%
This company
38.2%
Market median
-42% vs market
20202024
Return on equity
-3631.0%
This company
18.4%
Market median
-19834% vs market
20202024
Net profit margin
-11556.3%
This company
8.1%
Market median
-142770% vs market
20202024
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20202024
Debt / equity
3.53×
This company
0.62×
Market median
-469% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
MB Chief Executive Officer | Chief Executive Officer | 2021 – 2021 |
KS Chief Executive Officer | Chief Executive Officer | 2021 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Chairman | 2024 | |
| Former (9) | ||
| Board of Directors | 2023 – 2023 | |
| Board of Directors | 2021 – 2021 | |
| Board of Directors | 2023 – 2024 | |
| Chairman | 2023 – 2024 | |
| Board of Directors | 2023 – 2024 | |
| Board of Directors | 2021 – 2021 | |
| Chairman | 2021 – 2023 | |
| Board of Directors | 2021 – 2021 | |
| Chairman | 2021 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 26.57% | 26.57% | 2023 | |
| Company | 13.45% | 13.45% | 2023 | |
| Company | 7.58% | 7.58% | 2023 | |
| Company | 7.53% | 7.53% | 2023 | |
| Company | 7.43% | 7.43% | 2023 | |
| Individual | 5.3% | 5.3% | 2023 | |
| Company | 3.79% | 3.79% | 2023 | |
| Company | 3.05% | 3.05% | 2023 | |
| Company | 2.64% | 2.64% | 2023 | |
| Individual | 2.03% | 2.03% | 2023 | |
| Company | 1.84% | 1.84% | 2023 | |
| Company | 1.71% | 1.71% | 2023 | |
| Company | 1.6% | 1.6% | 2023 | |
| Company | 1.6% | 1.6% | 2023 | |
Goldman Sachs & Co. Llc | Company | 1.52% | 1.52% | 2023 |
| Individual | 1.52% | 1.52% | 2022 | |
| Company | 1.44% | 1.44% | 2023 | |
| Company | 1.22% | 1.22% | 2023 | |
| Individual | 1.01% | 1.01% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of REMOVAID AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Marte Bratlie | Chief Executive Officer | 0 companies |
| Kristin Sandereid | Chief Executive Officer | 0 companies |
| Kristin Østervold Odfjell | Board of Directors | 0 companies |
| Marianne Mowinckel | Board of Directors | 0 companies |
| Siri Stabel Olsen | Board of Directors | 0 companies |
| Trond Solberg | Chairman | 0 companies |
| Kristin Skau Åbyholm | Board of Directors | 0 companies |
| Hans Johan Hekland | Board of Directors | 0 companies |
| Joacim Holter | Chairman | 0 companies |
| Shantrez Monique Miller Gillebo | Board of Directors | 0 companies |
| Jostein Christian Dalland | Chairman | 0 companies |
| Cecilie Stenstadvold Sverdrup | Board of Directors | 0 companies |
| Masha Paule Nathalie Legris Strømme | Chairman | 0 companies |